نتایج جستجو برای: braf

تعداد نتایج: 7505  

Journal: :Annals of oncology : official journal of the European Society for Medical Oncology 2013
M Ilie E Long V Hofman B Dadone C H Marquette J Mouroux J M Vignaud H Begueret J P Merlio D Capper A von Deimling J F Emile P Hofman

BACKGROUND Non-small-cell lung carcinoma (NSCLC) patients with a BRAF(V600E) mutation benefit from targeted therapy. The usefulness of immunohistochemistry (IHC) as an alternative approach for the detection of BRAF(V600E) in NSCLC patients has not been evaluated until now. This study compared the specificity and sensitivity of IHC with other methods for the detection of BRAF(V600E) in primary l...

Journal: :European journal of endocrinology 2008
Luisa Barzon Giulia Masi Isabella Merante Boschin Enrico Lavezzo Monia Pacenti Eric Casal Ide Antonio Toniato Stefano Toppo Giorgio Palù Maria Rosa Pelizzo

INTRODUCTION Activating mutations of the BRAF oncogene are frequently detected in papillary thyroid carcinoma (PTC) and have been associated with a worse prognosis. The amino acid substitution V600E accounts for 90% of all oncogenic BRAF mutations and is typically detected in classic PTCs, whereas other less frequent BRAF mutations seem to be associated with other PTC histotypes. CASE Screeni...

2016
Tanja Dolinsek Lara Prosen Maja Cemazar Tjasa Potocnik Gregor Sersa

BACKGROUND The aim of the study was to explore the effectiveness of electrochemotherapy (ECT) during the treatment of melanoma patients with BRAF inhibitors. Its effectiveness was tested on BRAF mutated and non-mutated melanoma cells in vitro and in combination with BRAF inhibitors. MATERIALS AND METHODS ECT with bleomycin was performed on two human melanoma cell lines, with (SK-MEL-28) or wi...

2016
Young Jun Chai Jin Wook Yi Hyeon-Gun Jee Young A Kim Ju Han Kim Mingzhao Xing Kyu Eun Lee

BACKGROUND BRAFV600E is the most common mutation in papillary thyroid carcinoma (PTC), and it is associated with high-risk prognostic factors. However, the significance of the BRAF mRNA level in PTC remains unknown. We evaluated the significance of BRAF mRNA expression level by analyzing PTC data from The Cancer Genome Atlas (TCGA) database. METHODS Data from 499 patients were downloaded from...

2015
Dagmara Rusinek Michal Swierniak Ewa Chmielik Monika Kowal Malgorzata Kowalska Renata Cyplinska Agnieszka Czarniecka Wojciech Piglowski Joanna Korfanty Mykola Chekan Jolanta Krajewska Sylwia Szpak-Ulczok Michal Jarzab Wieslawa Widlak Barbara Jarzab Paula Soares

BACKGROUND The molecular mechanisms driving the papillary thyroid carcinoma (PTC) are still poorly understood. The most frequent genetic alteration in PTC is the BRAFV600E mutation--its impact may extend even beyond PTC genomic profile and influence the tumor characteristics and even clinical behavior. METHODS In order to identify BRAF-dependent signature of early carcinogenesis in PTC, a tra...

Journal: :Nuklearmedizin-nuclear Medicine 2022

Ziel/Aim Restoration of iodine incorporation (redifferentiation) was achieved in previously radioiodine-refractory, unresectable thyroid carcinoma by mitogen-activated protein kinase (MAPK) inhibition. However, redifferentiation unsatisfactory BRAFV600E mutated (BRAF-MUT) thus far. Here we assess safety and efficacy therapy through genotype-guided MAPK-modulation patients with BRAF-MUT or wild ...

Journal: :Cell 2016
Loredana Vecchione Valentina Gambino Jonne Raaijmakers Andreas Schlicker Arianna Fumagalli Mariangela Russo Alberto Villanueva Evelyne Beerling Alice Bartolini David G. Mollevi Nizar El-Murr Marielle Chiron Loreley Calvet Céline Nicolazzi Cécile Combeau Christophe Henry Iris M. Simon Sun Tian Sjors in ‘t Veld Giovanni D’ario Sara Mainardi Roderick L. Beijersbergen Cor Lieftink Sabine Linn Cornelia Rumpf-Kienzl Mauro Delorenzi Lodewyk Wessels Ramon Salazar Federica Di Nicolantonio Alberto Bardelli Jacco van Rheenen René H. Medema Sabine Tejpar René Bernards

BRAF(V600E) mutant colon cancers (CCs) have a characteristic gene expression signature that is also found in some tumors lacking this mutation. Collectively, they are referred to as "BRAF-like" tumors and represent some 20% of CCs. We used a shRNA-based genetic screen focused on genes upregulated in BRAF(V600E) CCs to identify vulnerabilities of this tumor subtype that might be exploited therap...

2015
Hiroyuki Mochizuki Matthew Breen

Activating mutations of the BRAF gene lead to constitutive activation of the MAPK pathway. The characterization and discovery of BRAF mutations in a variety of human cancers has led to the development of specific inhibitors targeting the BRAF/MAPK pathway and dramatically changed clinical outcomes in BRAF-mutant melanoma patients. Recent discovery of BRAF mutation in canine cancers underscores ...

Journal: :JAMA oncology 2015
James Larkin Christopher D Lao Walter J Urba David F McDermott Christine Horak Joel Jiang Jedd D Wolchok

IMPORTANCE The anti-PD-1 therapeutic antibody, nivolumab, has demonstrated clinical activity in patients with advanced melanoma. The activity of nivolumab in subgroups of patients with tumors which have wild-type BRAF kinase vs patients with tumors having mutant BRAF has not systematically been explored in a large dataset. OBJECTIVE To evaluate the efficacy and safety of nivolumab in patients...

Journal: :Cancer research 2006
Cleo Mesa Mana Mirza Norisato Mitsutake Maureen Sartor Mario Medvedovic Craig Tomlinson Jeffrey A Knauf Georg F Weber James A Fagin

Papillary thyroid cancers (PTC) are associated with nonoverlapping mutations of genes coding for mitogen-activated protein kinase signaling effectors (i.e., the TK receptors RET or NTRK and the signaling proteins RAS and BRAF). We examined the pattern of gene expression after activation of these oncoproteins in thyroid PCCL3 cells, with the goal of identifying pathways or gene subsets that may ...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید